Analysts project Q2 2026 revenue of $372.5 million and an EPS loss of $0.01, with the current $3.85 share price trading below the $4.50 average analyst target.
The primary focus for investors this quarter is the Insurance Medical Care Ratio (MCR), which indicates the company's ability to manage healthcare costs effectively.
Markets are also closely monitoring the growth of 'Counterpart Health,' the company's high-margin technology licensing arm that recently secured several external partnerships.
Success in these software-as-a-service initiatives is seen as the catalyst for achieving sustained GAAP profitability in the second half of 2026.